Peter
H. Langsjoen Short
Biography
Peter H. Langsjoen, M.D., F.A.C.C. has been practicing
cardiology 26 years since 1985. After
five years of invasive cardiology at the University of
Texas Health Center at
Dr. Peter Langsjoen is a founding member of the Executive
Committee of the International Coenzyme Q10 Association (www.ICQA.org), he is a Fellow of the American
College of Cardiology, a member of the Alpha Omega Alpha Honor Society,
American College of Physicians, Association of American Physicians and Surgeons,
Texas Club of Cardiologists, Texas Medical Association and Smith County Medical
Society. Coenzyme Q10
continues to be a major part of Dr. Langsjoen's clinical practice as well as an
ongoing research endeavor. Over the past
six years Dr. Langsjoen and his wife Alena have established a research
laboratory in
CURRICULUM VITAE
PETER H. LANGSJOEN, M.D.,
F.A.C.C.
DATE/PLACE
OF BIRTH: May 3, 1954,
Children - Jens,
OFFICE
ADDRESS:
E-MAIL ADDRESS: peterlangsjoen@cs.com
WORLD
WIDE WEB: www.ICQA.org
EDUCATION:
The
Chemistry with
Honors.
The
University of Texas Health Science Center,
The
Medicine
Residency, 1980-1983.
Fellowship,
1983-1985.
CERTIFICATIONS: Diplomate, American Board of
Internal Medicine, 1983.
Diplomate, American Board of
Internal Medicine, Cardiovascular Disease, 1985.
MEDICAL
LICENSURE: 1980 - present,
PROFESSIONAL
SOCIETIES: Alpha Omega Alpha Honor
Society - Member
Association of American
Physicians and Surgeons - Member
The International Coenzyme Q10
Association
- founding member of the executive committee 1997 to present www.ICQA.org
EXPERIENCE:
1983-1985: Involved in the first double blind controlled
study of coenzyme Q10 in cardiomyopathy with Per H. Langsjoen, M.D.,
F.A.C.C. during cardiology fellowship at Scott and
1985-1990:
Associate Professor of Medicine and staff invasive cardiologist at The
University of Texas Health Center at Tyler,
1986-1987:
Performed the first exploratory treatment of AIDS patients with coenzyme Q10
at the University of Texas Health Center in
1990-present: Private practice of non-invasive cardiology,
Presentations
at many conferences in countries worldwide, including the 6th, 8th and 9th
International Symposiums on the Biomedical and Clinical Aspects of Coenzyme Q
in Rome, Italy, 1990, in Stockholm, Sweden 1993 and in Ancona, Italy 1996,
respectively and at the First, Third, Fourth and Fifth Conferences of the
International Coenzyme Q10 Association in Boston, USA 1998, in
London, UK 2002, in Los Angeles, USA 2005 and in Kobe., Japan 2007.
1997:
Became a Founding Member of the Executive Committee of the International
Coenzyme Q10 Association, based in
2008-present:
Member of the Scientific Advisory Board of the Life Extension Foundation
Ongoing research into application of coenzyme Q10 to the treatment of broad range of cardiovascular diseases, including long term follow up study in heart failure, in primary and statin-induced diastolic dysfunction, hypertrophic cardiomyopathy and in hypertensive heart disease. Dr. Langsjoen and his wife, Alena, have accumulated much experience in monitoring plasma levels of both reduced coenzyme Q10 (ubiquinol) and oxidized coenzyme Q10 (ubiquinone) by electrochemical detection since 2004.
PUBLICATIONS:
1. Langsjoen, P.H. and
Langsjoen, A.M. Supplemental ubiquinol in
patients with advanced congestive heart failure. BioFactors 2008;32:119-128.
2. Langsjoen, P.H. Alleviating Congestive
Heart Failure with Coenzyme Q10. Life Extension Magazine 2008(Feb);14(2):48-55.
3. Vos E, Mascitelli L,
Langsjoen PH. Statin contraindicated in
heart failure. Angiology. 2008 Oct-Nov;59(5):640; author reply 641-2. Epub 2008 Sep 25. Comment
on: Angiology. 2008 Feb-Mar;59(1):5-8.
4. Littarru G.P., Langsjoen P. Coenzyme Q10
and statins: biochemical and clinical implications. Mitochondrion. 2007 Jun;7 Suppl:S168-74.
5.
Langsjoen P.H., Langsjoen J.O., Langsjoen A.M., Lucas
L.A. Treatment of statin adverse effects
with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors.
2005;25(1-4):147-52.
6.
Langsjoen
P.H., Littarru. G.P., Silver, M.A. Role of
concomitant coenzyme Q10 with statins for patients
with hyperlipidemia, Current Topics in
Nutriceutical Research 2005;3(3):149158.
7. Silver MA, Langsjoen PH,
Szabo S, Patil H, Zelinger A. Statin cardiomyopathy? A potential role for
Co-Enzyme Q10 therapy for statin-induced changes in diastolic
8. Silver, M.A., Langsjoen, P.H., Szabo, S., Patil, H., Zelinger, A. Effect of atorvastatin on left ventricular diastolic
function and ability of coenzyme Q10 to reverse that
dysfunction. American Journal of
Cardiology 2004; 94:1306-1310.
9. Langsjoen P.H, Langsjoen,
A.M. The clinical use of HMG
CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human
publications. BioFactors 2003;18:101-111.
10. Langsjoen P.H. Comment. J Am Coll Cardiol 2000 Mar 1;35(3):816-7.
11. Langsjoen P.H., Langsjoen
A.M. Overview of the Use of CoQ10
in Cardiovascular Disease. BioFactors
1999;9:273-284.
12. Langsjoen P.H., Langsjoen
A.M. Review of Coenzyme Q10 in Cardiovascular Disease with Emphasis
on Heart Failure and Ischemia Reperfusion.
13. Langsjoen P.H., Langsjoen
A., Willis A, Folkers, K. The Aging Heart: Reversal of Diastolic Dysfunction
Through the Use of Oral CoQ10 in the Elderly. Anti-Aging Medical Therapeutics, 1997,
R.M.Klatz and R. Goldman eds., Health Quest Publications, pp.113-120.
14. Langsjoen P.H., Langsjoen
A., Willis R., Folkers K. Treatment of Hypertrophic Cardiomyopathy with
Coenzyme Q10. Mol Aspects
Med, 1997;18 Suppl.:s145-s151.
15. Langsjoen P.H., Langsjoen
P.H., Willis R., Folkers K. Treatment of
essential hypertension with coenzyme Q10. Mol. Aspects of Med.
1994;15
Suppl. s265-s272.
16. Langsjoen H.A., Langsjoen
P.H., Langsjoen P.H., Willis R., Folkers K. (1994) Usefulness of coenzyme Q10
in clinical cardiology, a long-term study.
Mol. Aspects of Med. 15 Suppl. s165-s175.
17. Langsjoen P.H., Langsjoen
P.H., Folkers K. Isolated diastolic dysfunction of the myocardium and its
response to CoQ10 treatment.
Folkers, K., Mortensen
18. Folkers K., Langsjoen P.H., Langsjoen P.H.
Therapy
with coenzyme Q10 of patients in heart failure who are eligible or
ineligible for a transplant. Biochem
Biophys Res Commun 1992 Jan 15, 182(1):247-53.
19. Folkers K; Hanioka T; Xia
LJ; McRee JT Jr; Langsjoen P. Coenzyme Q10
increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to
patients having the AIDS related complex. Biochem Biophys Res Commun, 176:
2, 1991 Apr 30, 786-91.
20. Langsjoen P.H., Langsjoen
P.H., Folkers K., Richardson P. (1991)
Treatment of patients with human immunodeficiency virus infection with
coenzyme Q10. Folkers K., Littarru G.P., and Yamagami, T., (eds) Biomedical and Clinical Aspects of Coenzyme Q,
6:409-415.
21. Langsjoen P.H., Langsjoen,
P.H., Folkers, K. Long term efficacy and safety of coenzyme Q10
therapy for idiopathic dilated cardiomyopathy.
The American Journal of Cardiology, 1990;65:521
- 523.
22. Langsjoen P.H., Langsjoen
P.H., Folkers K. A six-year clinical study of therapy of cardiomyopathy with
Coenzyme Q10. Int. J.
Tiss. Reac. 1990; XII, vol. 3 pp. 169-171.
23. Langsjoen PH, Folkersn K, Lyson K, Muratsu K,
Lyson T, Langsjoen P. Pronounced
increase of survival of patients with cardiomyopathy when treated with coenzyme Q10
and conventional therapy. Int. J. Tissue React. 1990;12(3):163-8.
24. Langsjoen P.H., Folkers K.,
Lyson K., Muratsu K., Lyson T., Langsjoen Peter H. (1988) Effective and safe
therapy with coenzyme Q10 for cardiomyopathy. Klin. Wochenschr. 66:583-593.
25. Folkers K., Langsjoen P.H.,
Langsjoen P.H.,
26. Langsjoen P.H., Langsjoen
P.H., Morishita M., Muratzu K., Lyson K., Folkers K. The long-term value of Coenzyme Q10
in patients with cardiomyopathy. Biomedical
and Clinical Aspects of Coenzyme Q, Folkers K., Yamamura Y.,(eds),
Elsevier, Amsterdam 1986;5:303-308.